CTOs on the Move

True North Therapeutics

www.truenorthrx.com

 
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

True North Therapeutics raised $40M on 12/03/2015
True North Therapeutics raised $45M on 10/19/2016

Similar Companies

ApoCell

ApoCell is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arzeda

Arzeda The Protein Design Company is a synthetic biology company.

Apeel Sciences

We use our natural plant-based technologies to protect crops and harvested produce, helping to eliminate food spoilage and reduce reliance on chemicals. Accomplishing our mission means we will waste less food, water and energy, helping to preserve our natural ecosystems while creating economic opportunities for the 500 million small family farms worldwide. In the future, less food will be wasted, we will use smarter, more natural methods for growing and protecting crops, and there will be an abundance of fresh food for everyone.

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeekâ„¢, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.